Bill
Bill > S3478
US S3478
US S3478GAIN TOOLS Act of 2022 Generating Antibiotic Incentives Now Through Opening Opportunities to Leverage Science Act of 2022
summary
Introduced
01/11/2022
01/11/2022
In Committee
01/11/2022
01/11/2022
Crossed Over
Passed
Dead
01/03/2023
01/03/2023
Introduced Session
117th Congress
Bill Summary
A BILL To provide for the designation of biological products as qualified infectious disease products.
AI Summary
This bill, the Generating Antibiotic Incentives Now Through Opening Opportunities to Leverage Science Act of 2022 (GAIN TOOLS Act of 2022), expands the definition of "qualified infectious disease products" to include certain biological products, in addition to antibacterial and antifungal drugs, that are intended to treat serious or life-threatening infections, including those caused by resistant pathogens. The bill also provides priority review for these qualified infectious disease products that require clinical data to demonstrate safety or effectiveness, regardless of whether they are drugs or biological products.
Committee Categories
Health and Social Services
Sponsors (3)
Last Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (on 01/11/2022)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/117th-congress/senate-bill/3478/all-info |
| BillText | https://www.congress.gov/117/bills/s3478/BILLS-117s3478is.pdf |
| Bill | https://www.congress.gov/117/bills/s3478/BILLS-117s3478is.pdf.pdf |
Loading...